Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CT-0508

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

CARISMA Therap

Drug class:

HER2 inhibitor, Macrophage stimulant

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

mifamurtide (2)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

mifamurtide (2)

›

HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	CT-0508 Sensitive: B - Late Trials CT-0508 Sensitive : B	CT-0508 Sensitive: B - Late Trials CT-0508 Sensitive : B
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	CT-0508 Sensitive: C2 – Inclusion Criteria CT-0508 Sensitive : C2	CT-0508 Sensitive: C2 – Inclusion Criteria CT-0508 Sensitive : C2